27.06.2012 • News

Former Süd-Chemie Manager Hans-Joachim Müller to Leave Clariant

Dr. Hans-Joachim Müller, who is a member of the Executive Committee of...
Dr. Hans-Joachim Müller, who is a member of the Executive Committee of Clariant, has decided to leave the company on June 30, 2012.

Former member of the Managing Board of Süd-Chemie, Dr. Hans-Joachim Müller, who is now member of the Executive Committee of Clariant, has decided to leave the company on June 30, 2012, for personal reasons. His current responsibilities will be transferred to the other members of the Executive Committee.

After the acquisition of Süd-Chemie by Clariant, Müller was appointed member of the Executive Committee of the Swiss specialty chemicals manufacturer in July 2011. His responsibilities include Environment Safety & Health Affairs, Innovation Excellence, and the Business Units Catalysis & Energy, Emulsions, Detergents & Intermediates, and Oil & Mining Services.

Until March 31, 2012, he was a member of the Managing Board of Süd-Chemie. In this position, Hans-Joachim Müller was responsible for the entire Süd-Chemie operations since 2011. He initially joined the Managing Board of Süd-Chemie in 2007.

"I want to thank Hans Joachim Müller for his commitment and dedication during his time with our company, in particular for his contributions to the integration of Süd-Chemie during the recent 12 months," said Hariolf Kottmann, CEO. "I wish him all the best and continued success in his future endeavors."

Company

Logo:

Clariant International Ltd

Rothausstr. 61
CH-4132 Muttenz
Switzerland

Company contact







Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.